Floatz logo

Petosemtamab

Lung Cancer - Non Small Cell Squamous

Merus B.V.monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

46 Active assets in the Lung Cancer - Non Small Cell Squamous cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Hospital of Shandong University
Phase 4BBB
Carboplatin
zhang yi
Phase 3BBB
Docetaxel
Shanghai JMT-Bio Inc.
Phase 3BBB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 3BB
Gefetinib
Seoul Veterans Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Petosemtamab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
59 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Advanced/Metastatic Solid TumorsDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →